A Rankin County teenager’s life-changing medication is being denied approval by the U.S. Food and Drug Administration, leaving him and many others with rare diseases unsure of their futures.

Charges Behl, arrested on Wednesday on charges of, among others, receipt in interstate commerce of misbranded drugs and ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Ultragenyx Pharmacutical reported second-quarter revenue increased 13% year over year. The Novato-based company aims for ...

Thank you for inviting Senator Tillis’ office to participate in this listening session. Panelists were asked to address an issue impacting drug affordability and accessibility. I appreciate the ...

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

U.S. Defense Secretary Pete Hegseth announced Tuesday that a Confederate memorial would be reinstalled in Arlington Cemetery ...

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Astria took the candidate, a monoclonal antibody inhibitor of plasma kallikrein called navenibart, into a late-stage study off the back of a phase 1b/2 trial last year that tied the drug to up to a 92 ...